Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 25, 2012

Phase III Success for Oral Testosterone Replacement Therapy

  • Clarus Therapeutics reported positive topline data from a Phase III trial evaluating its oral testosterone replacement therapy CLR-610 in men with low serum testosterone. Results from the positive-controlled trial showed that 87% of 141 men treated with the drug achieved serum testosterone levels in the normal range (300–1,000 ng/dL) after 90 days of treatment. The average testosterone level achieved was 624 ng/dL.

    In comparison, 80% of 146 men treated with the transdermal T-gel testosterone replacement therapy achieved normal serum testosterone levels, which averaged at 480 ng/dL. To meet FDA efficacy guidelines for a testosterone replacement therapy 75% of treated men should achieve testosterone levels in the normal range after 90 days of therapy.

    “We are particularly excited about the significant number of men receiving CLR-610 who achieved normal testosterone levels in this study,” comments Bela S Denes, M.D., Clarus CMO. “Market research shows that men currently being treated for low T with transdermal or injectable products would overwhelmingly prefer an oral option. Thus, we believe CLR-610 will have strong appeal.”

    CLR-610 is Clarus Therapeutics' primary development candidate. The testosterone undecanoate prodrug has been formulated to facilitate absorption via the intestinal lymphatic pathway, and is taken orally twice a day as a softgel capsule.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Pharmacists and Prescription Drug Misuse Programs

Do you agree that pharmacists should make a greater effort to become more involved with prescription drug-monitoring programs?

More »